City of Hope

Academia Sinica

Taipei Medical University

California Institute of Technology

Ya-Huei Kuo

Guido Marcucci

Marcin Tomasz Kortylewski

Bin Zhang

Piotr Marek Swiderski

Wei-Jan Huang

Chung-I Chang

John J Rossi

William A Goddard, Iii

Si-ping Han

Lisa Scherer

The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.

Methods of using anti-MIR126 compounds

Disclosed herein are conditional siRNAs activatable by CBF&#x3b2;-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

Conditional-siRNAS and uses thereof in treating acute myeloid leukemia

Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

HDAC8 inhibitors for treating cancer

Growing community of inventors

Duarte, CA, United States of America

Ya-Huei Kuo